Nevertheless, the current study provides compelling novel evidence that caspase-2 is a potential target to correct obesity and its associated comorbidities: metabolic syndrome, insulin resistance/T2DM and NAFLD. This evidence concerns the gene CASP2 and obesity due to melanocortin 4 receptor deficiency.